R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Implications of regulatory and FDA guidance on diversity, eq...

Diversity in clinical trials is essential, but are research study sites implementing regulatory guidelines on diversity, equity, and inclusivity?

R&D

How to optimise commercial-scale ATMP manufacturing through ...

This is the second part of our series, "The ATMP Manufacturer's Guide to Commercialisation and cGMP Compliance".

R&D

How birth tissue donations are fuelling the cell therapy rev...

As the burgeoning field of cell therapy evolves, so do the practices around obtaining the raw biological material needed to create these life-changing treatments.

R&D

The power of data science platforms to cut through the compl...

Biopharmaceutical companies across the globe are rapidly expanding their pipelines as they aim to break new ground in different disease areas, on behalf of patients awaiting life-changing t

R&D

Talking techbio with NVIDIA: Accelerated computing, NLP, and...

As Genentech and NVIDIA enter into a multi-year strategic AI research collaboration to accelerate drug discovery and development, web editor Nicole Raleigh revisits a recent discussion with

R&D

A forgotten opioid epidemic, but a mounting problem

Deaths from opioid-related overdoses continue to grow in the US, but public health events of recent times mean that attention has been focused elsewhere.